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Abstract: Allergists/immunologists see patients with a variety of
skin disorders. Some, such as atopic and allergic contact dermatitis,
are caused by abnormal immunologic reactions, whereas others,
such as seborrheic dermatitis or rosacea, lack an immunologic basis.
This review summarizes a select group of dermatologic problems
commonly encountered by an allergist/immunologist.
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INTRODUCTION
Allergists/immunologists see patients with a variety of skindisorders. Some, such as atopic and allergic contact
dermatitis, are caused by abnormal immunologic reactions,
whereas others, such as seborrhoic dermatitis or rosacea, lack
an immunologic basis. This review summarizes a select
group of dermatologic problems commonly encountered by
an allergist/immunologist.
ATOPIC DERMATITIS
Atopic dermatitis (AD) is a chronic inflammatory skin
disease that is often associated with asthma and rhinocon-
junctivitis. Prevalence in the United States among school-age
children 5 to 9 years old is estimated to be 17%, the incidence
of which has increased over the past 30 years.1 Sixty percent
of affected individuals present with the disease in the first
year of life and 90% before 5 years of age.2 There is a strong
genetic predisposition, with a prevalence of 80% if both
parents have this disease.3
Clinical features of AD include pruritus, both localized
and generalized, a chronic and relapsing course, typical
morphology and distribution of the skin lesions (Fig. 1), and
a family history of atopy. The diagnosis is clinical because
specific laboratory tests and pathognomonic skin findings do
not exist (Table 1).
There are 3 forms of AD: acute, subacute, and chronic.
Acute AD is characterized by intensely pruritic, erythematous
papules associated with excoriations, vesiculations, and se-
rous exudates. Subacute AD is associated with erythematous,
excoriated, scaling papules. Chronic AD is associated with
thickened lichenified skin and fibrotic papules. There is
considerable overlap of these 3 forms, especially with chronic
AD, which can manifest in all 3 ways in the same patient.
The relationship between AD and causative allergens is
difficult to establish. However, clinical studies suggest that
extrinsic factors can impact the course of disease. Therefore,
in some cases, it is helpful to perform skin testing on foods
that are commonly associated with food allergy (wheat, milk,
soy, egg, peanut, tree nuts, molluscan, and crustaceous shell-
fish) and aeroallergens to rule out allergic triggers that can
sometimes exacerbate this disease. Many patients are also
infected or colonized with Staphylococcus aureus and are
susceptible to contract herpes simplex, Molluscum contagio-
sum, or Trichophyton rubrum.
Genetic associations contributing to skin barrier break-
down include a loss-of-function mutation in the filaggrin
gene, which encodes a protein that is essential to maintain the
formation of the stratum corneum barrier.4 Polymorphisms in
the SPINK5 gene, which encodes a protein that inhibits serine
protease, and malfunctioning stratum corneum chymotryptic
enzymes, also contribute to impaired stratum corneum integ-
rity and function.5,6 AD has also been associated with toll-like
receptor (TLR)-2 gene polymorphisms and reduced produc-
tion of skin defensin and cathelicidins.7,8
Once an antigen, such as house dust mite allergen,
passes through the epidermal skin barrier, a number of im-
munoregulatory abnormalities involving both innate and
adaptive immunity occur. Antigen presenting cells in the
epidermis, such as Langerhan’s cells and dendritic cells, are
present in higher numbers compared with skin from normal
subjects. B lymphocytes from patients with AD also make
increased amounts of IgE. This cascade of events results in
excessive stimulation of T lymphocytes that, in turn, increase
the production of proinflammatory cytokines interleukin
(IL)-4, IL-5, and IL-13. There has also been a suggested role
of CD4CD25FOXP3 regulatory T cells to promote a TH2
immune response in the skin.9
Treating AD is comprehensive and begins with avoidance
of triggers such as irritating fabrics, soaps, and chemicals.
Exacerbating factors include excessive humidity, tight-fitting
clothing, and excessive hand washing and sweating. Oral anti-
histamines, particularly first-generation antihistamines, can help
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control pruritus and assist with sleep because of their sedative
effects. Liberal use of moisturizers and emollients with oral
vitamin D supplementation can help restore and preserve the
stratum corneum barrier. Topical corticosteroids reduce inflam-
mation, pruritus, and S. aureus colonization. Topical calcineurin
inhibitors also reduce inflammation by blocking T-cell activa-
tion in the skin without the potential side effects of moderate- to
high-potency corticosteroids. They also can be used on the
eyelids and face. Treatment with systemic antimicrobials is
sometimes necessary to control bacterial or fungal superinfec-
tions. Severe or recalcitrant disease can be treated with systemic
corticosteroids and occlusive wet dressings to hydrate the most
severely affected areas.
PITYRIASIS ALBA
Pityriasis alba is often considered to be a mild form of
atopic dermatitis.10 The disease affects 5% of children aged 3
to 16 years with improvement after puberty. The lesions
mostly affect the face, neck, and upper extremities but can
also occur on the trunk and lower extremities. The rash
initially appears as mildly erythematous and scaly circular
plaques, 0.5 to 2 cm in diameter, followed by hypopigmen-
tation (Fig. 2). The hypopigmentation may be more conspic-
uous in dark-skinned individuals and typically lasts several
months, but can remain for more than 1 year. The lesions are
usually asymptomatic, but patients may complain of local
itching or burning.
Etiology is unknown, but a connection with atopy has
been suggested, thus making it important to inquire about
personal or family history of atopic diseases such as asthma,
allergic rhinitis, or eczema. The condition can be exacerbated
by excessive, unprotected sun exposure and environmental
factors such as temperature and humidity.11 Differential di-
agnosis includes other disorders that cause hypopigmentation
such as vitiligo, tinea versicolor, halo nevus, and nevus
depigmentosus. Although unnecessary for diagnosis, histol-
ogy will show nonspecific acanthosis and mild spongiosis
with moderate hyperkeratosis and patchy parakeratosis.12
Pityriasis alba responds very well to topical moisturiz-
ers and emollients. The lesions typically resolve spontane-
ously without further treatment, but topical hydrocortisone
(1% or 2.5%) or tacrolimus can be used to relieve symptoms
such as itching caused by inflammation.
ALLERGIC CONTACT DERMATITIS
The skin is the first organ to encounter environmental
irritants and allergens. Allergic contact dermatitis (ACD)
is caused by a type IV or delayed-type hypersensitivity
reaction. The T lymphocytes are sensitized by a contact
allergen on the skin, such as oil from poison ivy, and upon
re-exposure, these sensitized T cells trigger an inflamma-
tory response at the site of skin contact, producing an
extremely pruritic, erythematous, papulovesicular rash
with scaling and dryness of the skin.
FIGURE 1. Atopic dermatitis. Note erythema and scaling of
flexural areas. Reprinted with permission from Habif, Clinical
Dermatology, 5th ed. Elsevier, 2009.
TABLE 1. Criteria for the Diagnosis of Atopic Dermatitis
Pruritus (or parental report of skin rubbing or scratching) plus 3 of the
following:
● Involvement of skin creases (antecubital, popliteal fossa, eyelid, neck)
● History of asthma or hay fever (or history of atopic disease in a first-
degree relative if the child is 4 years old)
● Generally dry skin in the past year
● Onset when child was 2 years old (only applies if child is 4
years old)
● Visual flexural dermatitis
Table reprinted with permission from reference.4
FIGURE 2. Pityriasis alba hypopigmentation. Reprinted with
permission from Habif, Clinical Dermatology, 5th ed. Elsevier,
2009.
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Haptens are low molecular weight compounds, not
inherently immunogenic, and most are highly lipophilic and
readily pass through the epidermis, binding covalently to
epidermal proteins, which act as carrier proteins. This antigen
hapten-carrier protein complex is taken up by cutaneous
dendritic cells and presented to T lymphocytes in the context
of the major histocompatibility complex classes I and II.
These cells then migrate from the skin to the regional lymph
nodes where the hapten-protein complex is presented to both
CD4 and CD8 T lymphocytes, which are then primed and
able to specifically recognize the hapten-protein complex.
The T cells enter the circulation, ending the sensitization
phase, 10 to 15 days after the initial contact with the hapten.
Upon future cutaneous exposure to the same hapten,
sensitized T cells in the dermis and epidermis undergo recruit-
ment and recognize the hapten-protein complex in the context of
major histocompatibility complex classes I and II, become
activated, and produce interferon- and other cytotoxic mole-
cules that stimulate resident inflammatory skin cells to produce
additional inflammatory mediators. Lastly, polymorphonuclear
cells, monocytes, and additional T cells are recruited to the
inflamed skin which undergoes morphologic changes.
The most common histologic feature of acute ACD is
spongiosis of the lower epidermis as a result of intercellular
edema characterized by lymphocytic infiltration of the
perivascular tissues and epidermis. In chronic stages, the
edema and spongiosis is replaced by hyperplasia and parak-
eratosis of cells in the epidermis.
Clinically, the elicitation phase appears approximately
24 to 96 hours after exposure to the antigen to which the
susceptible individual is sensitized. In the acute phase, the
skin is erythematous, edematous, and very pruritic, but soon,
papules and vesicles appear, which can blister, ooze serum,
and eventually crust over (Fig. 3). In the chronic stage,
exacerbated by scratching, the skin becomes lichenified,
cracked, and hyperpigmented.
Some of the most common sources of allergens to cause
ACD are metals, skin care products, clothing, medications,
and plants. Nickel is the most common metal sensitizer,
particularly among women who become allergic to nickel-
containing jewelry. Chromate is a common cause of ACD
among men, usually related to occupational exposures from
cement, chrome-tanned leather, paint, bleaches, and printing
solutions. Cosmetics and other skin care products can cause
ACD from a variety of chemicals, including preservatives,
excipients, perfumes, active or inactive ingredients, emulsi-
fiers, and sunscreens. Many skin care products now provide
ingredient labels in an effort to reduce the risk of allergic
reaction among sensitized individuals. Common clothing sen-
sitizers include dyes, adhesive resins, and chemicals or anti-
oxidants used in manufacturing synthetic fabrics. The axilla
is particularly prone because it is an area of high moisture and
friction associated with wearing clothing. Topical medica-
tions such as antimicrobials, anesthetics, and antiseptics can
cause ACD through active ingredients and preservatives.
Reactions are usually localized to the area of application, but
systemic reactions also can occur if a sensitized patient is
given a medication orally or parenterally that contains the
antigen or cross-reacts with any agent to which the patient is
sensitized. An example of this is systemic corticosteroid
administration in a patient who has been sensitized and
develops ACD after using topical corticosteroids. Plants are
one of the most common causes of ACD in the United States,
with 50% of adults being sensitive to urushiol, the hapten
found in poison ivy, poison oak, and poison sumac.13
A detailed and methodically obtained history with
questions focusing on occupations, hobbies, home environ-
ment, clothing, and personal objects in contact with the skin
is necessary to make this clinical diagnosis. The appearance
and distribution of the affected skin often provide clues to the
agent causing the disease; for example, nickel dermatitis
affects areas of skin that are in contact with jewelry, blue
jeans buttons, wrist watches, and other metallic objects.
Ingredients of nail polish can sometimes cause periorbital
skin itching and lichenification.
If a history and physical examination does not reveal a
causative agent, patch testing can be used to attempt to detect
the contact allergen. The most common contact allergens
have been identified and grouped into a series of patch tests
and are available in products such as T.R.U.E.TEST (Aller-
derm, Phoenix, AZ). Individual tests can also be selected and
applied by the allergist using Finn Chambers (Epitest, Fin-
land) in either aqueous or petrolatum base. This latter method
also allows testing to the patient’s own products. Patch tests
are applied to the upper back for 48 hours. Reading is done
the day the patches are removed, at 48 hours, and again in 72
FIGURE 3. Poison ivy rash with vesicles, blisters, and linear
lesions. Reprinted with permission from Habif, Clinical Der-
matology, 5th ed. Elsevier, 2009.
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hours. Results of patch tests must be carefully correlated with
the clinical history. A grading scale for reading patch tests is
summarized in Table 2.
Treatment of ACD is based on identification and elim-
ination or avoidance of the offending contact allergen. Pa-
tients should be educated on allergen identification, its known
or potential sources, and cross-reacting substances (ie, skin of
mango fruit protein cross-reacting with urushiol of poison
ivy). Pruritus can be relieved with cold compresses, topical
calamine or oatmeal, aluminum acetate, and moisturizers.
Topical steroids can be used in the acute phase to control
inflammation and inhibit pruritus. Short bursts of systemic
corticosteroids can be used in severe, extensive dermatitis.
SEBORRHOIC DERMATITIS
Seborrhoic dermatitis is a skin disorder affecting areas
rich in sebaceous glands. The inflammation is chronic and
relapsing in nature and primarily affects the scalp, face, chest,
and intertriginous areas (Fig. 4). People of all ages can be
affected, but clinically significant disease usually affects
persons aged 35 to 44 years and less commonly among those
younger than 12 years.14 The disease is also more severe in
patients infected with human immunodeficiency virus, espe-
cially if the CD4 T-cell count is 400 cells per millili-
ter.15,16 There is no sex predilection, but the disease rarely
affects African Americans.
Multiple causes of seborrhoic dermatitis have been
postulated. Malassezia fungus species is considered the most
likely pathogenic cause. The fungus has been shown to be
present on affected skin and the dermatitis responds to anti-
fungal treatment. Malassezia fungus sp. is also present on
the skin of individuals unaffected by seborrhoic dermatitis,
which suggests a possible predilection for the disease as a
result of a dysfunctional immune response.17 Other pro-
posed causes include stress, exposure to solar ultraviolet
radiation, hormone levels causing hyperfunctioning of se-
baceous glands, and nutritional deficiencies; however,
these are unproven.18
Tissue histology of affected skin shows epidermal cell
proliferation with focal parakeratosis. More severely affected
areas can show spongiosis caused by dermal edema and
neutrophil infiltration at the lesion margins. Parakeratosis is
more widespread in chronic lesions and in patients with
advanced human immunodeficiency virus.17,19
Topical antifungal preparations are the most effective
and safest method for treating seborrhoic dermatitis. Keto-
conazole 2% (shampoo, gel, foam, and cream), bifonazole
1% (shampoo and cream), and ciclopirox olamine 1% to
1.5% (shampoo and cream) should be applied to the scalp 2
to 3 times a week for initial clearance and then once a week
to maintain remission. Treating nonscalp skin requires daily
or twice daily application for clearance and daily use for
maintenance.
Other treatment options include topical calcineurin in-
hibitors, selenium sulfide shampoos (scalp only), topical
corticosteroids, topical lithium gluconate or succinate (non-
scalp only), coal-tar shampoos (scalp only), and ultraviolet B
light phototherapy. However, they are less effective than
topical antifungal treatment. There are sparse clinical data on
efficacy of systemic antifungal agents, with trials showing
either no benefit compared to placebo20 or only improving
skin that is usually covered, such as the scalp or torso.21
Hepatotoxicity and the required laboratory monitoring should
be weighed carefully when considering this class of medica-
tion.18
ROSACEA
Rosacea is a chronic inflammatory skin disorder affect-
ing 14 million people in the United States, most commonly
women aged 30 to 50 years.22–24 Disease in males can be
more severe with a higher incidence of complications.25–28
Risk factors include chronic actinic damage, use of topical
corticosteroids, a spontaneous tendency for flushing, genetic
factors, and northern or eastern European descent.25,28
The face is the most commonly affected part of the
body with erythema, flushing, telangiectasias, papules, pus-
tules, and edema of the nose, cheeks, chin, forehead, and
glabela (Fig. 5).25,26,29 Lesions are symmetrical and spare the
periocular region and the papules do not form comedones,
distinguishing them from acne.
There are 4 phenotypes of rosacea as proposed by the
National Rosacea Society Expert Committee in 2002.30 Pap-
TABLE 2. Grading Scale for Recording Results of Cutaneous
Patch Test13
NR Negative reaction
? Doubtful reaction (weak erythema only)
 Weak positive reaction: erythema, induration, possibly papules
 Strong positive reaction: erythema, induration, papules, vesicles
 Extreme positive reaction: intense erythema and induration,
coalescing vesicles, bullous reaction
IR Irritant reaction
Adapted with permission from reference.13
FIGURE 4. Seborrhoic dermatitis affecting nasolabial folds.
Reprinted with permission from Habif, Clinical Dermatology,
5th ed. Elsevier, 2009.
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ulopustular, or classic rosacea, is characterized by central
facial papules and pustules. Chronic erythema with intermit-
tent flushing can lead to edema of the forehead, glabela, nose,
and cheeks. In erythematotelangiectatic rosacea, a history of
flushing is the most important clinical feature. Flushing can
be triggered by skin care products or topical medications,
often lasts beyond 10 minutes, and can result in chronic
edema, telangiectasia, and edema of the central face. Phyma-
tous rosacea more commonly affects men and is characterized
by pustules, papules, thickened skin, enlarged follicular ori-
fices, and telangiectasias. This subtype most commonly af-
fects the nose, but the forehead, chin, ears, and eyelids can
also be involved. Lastly, ocular rosacea affects the eyelid,
conjunctiva, and cornea. Patients can present with symptoms
including blepharitis, conjunctivitis, and corneal lesions,
which can lead to opacification, scarring, or vision loss.
The pathophysiology of rosacea is not well understood
but several mechanisms have been suggested. Vascular dis-
ease may contribute to rosacea by predisposing individuals to
vasodilation via an abnormal response to thermoregulation.
This postulate is supported by the finding that certain
triggers for flushing, such as alcohol, spicy food, exercise,
menopause in women, emotional stress, and warm envi-
ronmental temperatures, can worsen rosacea.26 Repeated
flushing eventually leads to permanent dilation of blood
and lymph vessels in the skin.31–33
The innate immune system may also be dysregulated,
specifically, cytokine signaling and upregulation of proin-
flammatory molecules such as cathelicidin, as a result of
toll-like receptor signaling in the skin. Other pathogenic
mechanisms include overproduction of reactive oxygen
species from neutrophils, exposure from ultraviolet light,
cutaneous proteases, such as kallikrein-5, and microbial
involvement from organisms Demodex folliculorum and
Helicobacter pylori. Each of these causes share a common
feature of promoting direct damage and inflammation to
skin, sebaceous glands, or hair follicles.34
Diagnosis is clinically based on a patient’s history and
presence of characteristic skin findings. History should focus on
precipitating or alleviating factors, duration and frequency of
episodes, and lesion morphology and time course. On physical
examination, patients should have at least one of the following
features affecting the convex areas of the face: transient flushing,
papules, pustules, persistent erythema, and telangiectasia. Burn-
ing, pruritus, plaques, edema, and dryness of skin can also be
present. There are no diagnostic tests to confirm rosacea. If skin
biopsy is done during the acute phase, histology will show
perivascular lymphocytic infiltrate, telangiectasias, and neutro-
phil and lymphocyte infiltration around follicular infundibula.
Chronic lesions will demonstrate more neutrophils within the
follicles and infiltration of lymphocytes, epitheliod cells, and
histiocytes around follicles. Noncaseating epitheliod granulomas
can also be seen and will be surrounded by lymphocytes and
plasma cells. The upper dermis will contain marked telangiec-
tasias and actinic elastosis.26
Treatment of rosacea is targeted toward the specific symp-
toms and phenotype classification. There are 5 general catego-
ries of treatment options: topical metronidazole, topical azelaic
acid, topical benzoyl peroxide combined with topical antimicro-
bials, oral antimicrobials, and a miscellaneous group. Topical
metronidazole (0.75%, 1%) or azelaic acid (15% gel, 20%
cream) are both equally effective for pustular/papular dis-
ease35,36 and superior to placebo.37–39 Pustular/papular disease
can also be treated with clindamycin lotion, permethrin 5%
cream, tretinoin cream, or sulfacetamide 10%/sulfur 5%.
Oral antibiotics can be used for more extensive pus-
tules/papules. Oral metronidazole and tetracycline have equal
clinical efficacy40 with one trial showing oral tetracycline to
be superior to placebo according to physician assessment.41,42
Oral erythromycin and ampicillin can also be considered, but
these and other oral antimicrobials should be switched to
topical agents once clinical improvement is achieved.
Oral isoretinoin can be used for severe or refractory
rosacea but should be used with caution in women of repro-
ductive age and laboratory monitoring for hepatotoxicity and
dyslipidemia is suggested. Ocular treatment options include
topical metronidazole or oral tetracycline, and laser photo-
therapy can alleviate symptoms of rhinophyma.43
PITYRIASIS ROSEA
Pityriasis rosea is a common, benign skin condition that
accounts for 3% of visits to dermatologists in North America.
Most cases occur among older children and young adults
between the ages of 10 and 35 years; it is rare in infants and
the elderly. The disease affects both sexes and all ethnic
groups equally and may occur at any time of year but is most
common during colder months.44 The etiology of pityriasis
FIGURE 5. Rosacea erythema and few pustules affecting
the face. Reprinted with permission from Habif, Clinical Der-
matology, 5th ed. Elsevier, 2009.
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rosea is unknown, but researchers have been investigating
viruses such as human herpes virus 6 and 7 as possible
causes.45–47 The rash does not spread by casual contact.
Clinically, this disease begins in about 50% of patients
as a viral prodrome with headache, malaise, and pharyngitis.
The skin then develops a single “herald” patch, pink or
salmon in color and round or oval in shape with a diameter of
2 to 10 cm that typically appears on the neck, chest, or back.
The herald patch then scales at the margins, imitating eczema
and tinea corporis.48
Several days or weeks after the herald patch appears,
new crops of smaller lesions 5 to 10 mm in diameter appear
on the torso or, less commonly, the extremities (Fig. 6). These
secondary lesions follow the contours of the cleavage lines of
the skin (also called Langer lines). This is where the charac-
teristic “Christmas tree” pattern can be visualized when
lesions align along the oblique contours of the back.48
The rash tends to spread in a centrifugal pattern into the
extremities and usually clears within 4 to 6 weeks but can
occasionally persist for several months. The erythema, des-
quamation, and scaling resolves completely, but postinflam-
matory hyperpigmentation may persist for several months.
Pityriasis rosea is a clinical diagnosis based on the
presence of a herald patch by history or examination, time,
appearance and distribution of secondary lesions, and the lack
of other symptoms such as pruritus. The differential diagnosis
includes tinea corporis, secondary syphilis (if the palms and
soles are affected and the patient is sexually active), nummu-
lar eczema, guttate psoriasis, viral exanthema, lichen planus,
and drug rash. Skin biopsy is not necessary to make the
diagnosis, but if done, it will show focal parakeratosis with or
without acanthosis, spongiosis, perivascular lymphocyte, or
histiocyte infiltrates and red blood cell extravasation.
Most cases do not require treatment and resolve within 5
to 8 weeks. Pruritus may be a significant symptom in 25% of
patients,49 which can be treated with topical agents such as Sarna
or calamine lotion, zinc oxide, low- to moderate-potency topical
corticosteroids, and oral antihistamines.50 Clinical studies using
oral antimicrobial medications erythromycin51–53 and azithro-
mycin54 and antiviral treatment using acyclovir55 have not dem-
onstrated clear benefit and are not recommended. Referral to a
dermatologist should be considered in patients whose rash lasts
beyond 3 months or if phototherapy with ultraviolet light is
being considered for extensive disease.
ACNE
In Western cultures, acne affects up to 95% of adolescents
and persists into middle age in 12% of women and 3% of men.
It can vary in severity, from a few pustules and comedones to
highly inflamed, cystic lesions that leave scars on both skin and
psyche. Severe disease is more common among males, but the
disease is more persistent in females, with exacerbations related
to menstrual periods and pregnancy.44
Acne is the result of a combination of several patho-
genic factors that involve the pilosebaceous unit of the skin
and is most frequent and intense in areas where sebaceous
glands are largest and most numerous (face, chest, back, and
upper outer arms). Overproduction of sebum from sebaceous
glands is considered to be the most important pathogenic
factor in the formation of acne. Increased amounts of sebum
lead to follicular hyperkeratosis and plugging of the pilose-
baceous duct. The result is a follicular plug and formation of
a closed comedone (firm, white papule) or open comedone
(blackhead) if the follicle orifice reopens.56
Another important cause of acne is bacterial over-
growth of Propionibacterium acnes, a normal skin flora that
is not normally pathogenic. P. acnes produces proinflamma-
tory products such as lipases, superoxide radicals,57 pro-
teases, and hyaluronidase, which are primary irritants and
comedogenic, and chemotactic factors that attract neutrophils
to potentiate the inflammatory response.58 Inflammatory cy-
tokines such as interleukin-1 and leukotriene B4 and andro-
gen hormones have also been identified as key components of
acne pathophysiology.59 P. acnes also interacts with cells via
membrane toll-like receptors 2 and 4.60
Acne is diagnosed based on an evaluation of lesions and
their complications, which include drainage and hemorrhage
from lesions and pain that can be associated. Acne lesions are
categorized as either noninflammatory (open or closed come-
dones) or inflammatory (papules, pustules, and nodules). Inflam-
matory nodules are further graded in severity based on number
of pustules/papules/nodules, occupational disability, psychoso-
cial impact, and the failure of response to previous treatment.
Grading classification is summarized in Figure 7.
Current acne treatments include oral and topical anti-
biotics, topical retinoids, benzoyl peroxide, azelaic acid, oral
FIGURE 6. Pityriasis rosea fully evolved two weeks after on-
set. Reprinted with permission from Habif, Clinical Dermatol-
ogy, 4th ed. Elsevier, 2004.
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isoretinoin, and hormonal therapy only in women. Mild-
moderate acne can be treated with benzoyl peroxide, a
topical antibiotic, and a retinoid. Options for topical anti-
biotics include erythromycin and clindamycin gels, pico-
linic acid gel (10%), and dapsone gel (5%). Additional
efficacy and compliance can also be attained with combi-
nation topical medications such as clindamycin/zinc ace-
tate, clindamycin/benzoyl peroxide, or clindamycin/treti-
noin gels. These should be applied at the lowest dose and
frequency that controls disease.
If acne lesions do not improve after several weeks or
for patients with moderate-severe disease, topical medica-
tions should be applied twice daily with addition of oral
antibiotics if there are extensive pustules and/or nodules.
Antibiotics such as tetracyclines, trimethoprim, and mac-
rolides are the mainstay of treatment for moderate-severe
acne, beneficial for both their antimicrobial and anti-
inflammatory properties.61– 63 Resistance of P. acnes to
antibiotics is a growing problem, mostly with erythromy-
cin, less so with trimethoprim, doxycycline, and tetracy-
cline, and rarely with minocycline.64,65 Acne can also be
treated with oral lymecycline66 (a second-generation tetra-
cycline) and subantimicrobial doses of doxycycline67 (20
mg twice daily), and azithromycin is an option for use in
pregnant women.68,69 Oral antibiotics should be tapered
and discontinued if lesions are improving and patients can
be maintained on topical therapies.
Oral isoretinoin (13-cis-retinoic acid) is approved for
treatment of severe nodular acne or for acne that is resistant to
treatment or causing physical or psychological scarring.61 This
medication should be prescribed under the direction of a derma-
tologist and with female patients required to use some form of
contraception or abstinence because of potential fetal abnormal-
ities that can occur in pregnant women who take this medication.
Photodynamic light can also be used to induce formation of
porphyrins on the skin that can be activated by visible light,
enabling them to destroy bacteria-causing acne.70
TINEA
Tinea are aerobic fungi that can be hosted on humans
(anthropophilic), and animals (zoophilic) and in the soil
(geophilic). There are 3 genera of dermatophytes: Trichophy-
ton, Epidermophyton, and Microsporum. Direct contact with
any of these organisms can lead to infection of the stratum
corneum skin layer. Some individuals, however, will be
asymptomatic carriers and may spread the organism to per-
petuate infections.71,72
Tinea refers to dermatophyte infection of the skin and
is grouped according to lesion location: tinea capitis (scalp),
tinea cruris (Fig. 8a; groin), tinea pedis (Fig. 8b; feet), tinea
FIGURE 7. Acne classification
and grading. Habif, Clinical Der-
matology, 5th ed. Elsevier, 2009.
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corporis (Fig. 8c; body), tinea unguium (nails, also known as
onychomycosis), tinea faciale (face), tinea barbae (beard),
and tinea manuum (hands/palms).
Infection is caused by dermatophyte invasion of the
stratum corneum and keratinized layer of the outer skin.
Dermatophytes produce enzymes such as keratinase, which
helps them penetrate tissue and enables their hyphae to
invade and spread outward. Dermatophytes can also invade
hair shafts, as in tinea capitis. Host defenses against dermato-
phytes include increasing the rate of epidermal turnover,
increasing fatty acid content of sebum, and cell-mediated
adaptive immune defense with T lymphocytes.72
Tinea capitis is the most common fungal infection in
children, with 90% of cases in the United States caused by
Trichophyton tonsurans. Infection is limited to the scalp and
typically presents with scaling, patchy alopecia with local
erythema, pruritus, pustules and black dots (hair shafts bro-
ken off at follicular orifice). Suboccipital or posterior cervical
lymphadenopathy can also be present.72
Tinea corporis, also known as ringworm, is most com-
monly caused by the Trichophyton species in the United
States. Only glabrous (smooth and bare) skin is affected.
Early lesions appear as red, scaly papules that spread outward
and coalesce into annular patches or plaques. These patches
or plaques then develop a raised outer edge with central
clearing caused by increased epidermal cell turnover.
Tinea cruris is a dermatophyte infection of the groin
most commonly caused by T. rubrum, Trichophyton menta-
FIGURE 8. A, Tinea cruris; B, tinea pedis; C, tinea corporis.
Reprinted with permission from Habif, Clinical Dermatology.
4th ed. Elsevier, 2004; 5th ed, Elsevier, 2009.
FIGURE 9. Lichen planus with characteristic purple papules
and Wickham’s striae. Habif, Clinical Dermatology, 4th ed.
Elsevier, 2004.
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grophytes, and Epidermophyton floccosum. Also known as
“jock itch,” this infection occurs more frequently in adoles-
cent and adult males.72 Infection is favorable in warm, humid
environments and can be enhanced by wearing wet or tight-
fitting clothing.73 The rash primarily affects the proximal
medial thighs, but can also extend onto the buttocks and
lower abdominal wall. The scrotum is usually not affected.
Intense pruritus and burning are the main symptoms of this
rash, which appears as multiple pustules and vesicles with a
raised, leading edge surrounded by skin that is erythematous
and scaling.73
Tinea pedis, or athlete’s foot, can be caused by the
same organisms that cause tinea cruris, and as such, the feet
should also be examined as a possible source for groin
involvement. There are 3 presentations for tinea pedis. The
most common form, called intertriginous or interdigital, is
characterized by erythema, scaling, foul odor, fissuring, and
cracking of the toe web spaces. A second form, moccasin
type, demonstrates erythema, scaling, fissuring, dryness, and
hyperkeratosis on the plantar and lateral margins of the foot.
Finally, the vesiculobullous form presents with vesicles and
large bullae, usually affecting the soles.72,73
Most tinea infections can be diagnosed on the basis of
history, physical examination, and direct microscopic exam-
ination of affected tissue scrapings stained with potassium
hydroxide. Fungal culture can be useful when long-term
treatment is anticipated, if infections are resistant to standard
therapy, or if the diagnosis is uncertain.71
Treatment options for tinea infections include both
topical and oral antifungal medications. Tinea cruris and
corporis can usually be treated with topical agents such as
terbinafine or butenafine cream. Topical agents should be
applied once to twice daily at least 2 cm beyond the margins
of the rash for 2 to 4 weeks and continued for 1 week after the
rash resolves. Low-potency topical corticosteroids can also
be used for short periods to reduce acute inflammation. Oral
antifungal agents are rarely needed to treat tinea cruris and
corporis, except for severe or refractory infections.
Infection of the hair or nails as seen in tinea capitis,
tinea barbae, and tinea unguium, however, requires systemic
antifungal therapy because topical agents do not sufficiently
penetrate the hair root or nail bed. Oral griseofulvin (20
mg/kg per day for 8 weeks) is often the first choice because
of its proven efficacy and safety profile. Laboratory monitor-
ing for hepatic toxicity is not required. Oral terbinafine (62.5
to 250 mg/kg per day based on weight) is an appealing option
because of its ability to clear infection in 4 weeks, but
laboratory monitoring for hepatic toxicity is necessary. Ad-
junctive use of antifungal shampoos is also recommended
when treating patients with tinea capitis as well as close
contacts in an effort to reduce spore counts and inhibit
transmission. Selenium sulfide 2.5% and ketoconazole sham-
poos are the most commonly recommended. Children should
continue to attend school because spore shedding can con-
tinue for months and asymptomatic carriers are common in
the general population.72
LICHEN PLANUS
Lichen planus is an inflammatory reaction involving the
skin and mucous membranes. The disease mostly affects
middle-aged adults; children are rarely affected. Etiology is
not known, but 10% of patients have a positive family
history, suggesting a possible genetic link,74 particularly with
human leukocyte antigen (HLA)-DR1.75 Liver disease may
also be a risk factor, especially in patients with hepatitis
C.76,77 Medications have also been implicated in inducing
lichen planus, including beta blockers, methyldopa, penicil-
lamine, quinidine, nonsteroidal anti-inflammatory drugs,
angiotensin converting enzyme inhibitors, sulfonylureas, car-
bamazepine, gold, lithium, and quinine.78
There are several clinical forms of lichen planus,
each sharing a common lesion morphology and distribu-
tion. The rash appears as a flat-topped, polyangular, vio-
laceous papule. Patients will experience pruritus, pain if
the papules ulcerate, and postinflammatory hyperpigmen-
tation of affected areas. Closer examination of the surface
reveals a lacy, reticular pattern of criss-crossed white lines
called Wickham striae (Fig. 9).44
The lesions typically affect the skin, nails, mucous
membranes, vulva, and penis.79 In the most common local-
ized papular form, the papules usually affect the flexor
surfaces of the extremities, especially the wrists and fore-
arms, lower legs, and back. Some will undergo spontaneous
remission within a few months, but most lesions become
chronic and last an average of 4 years.44
FIGURE 10. Ictus reaction from insect bites. Habif, Clinical
Dermatology, 4th ed. Elsevier, 2004.
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Hypertrophic lichen planus, the second most common
form, can affect any part of the body, but has a predilection
for the pretibial areas and ankles. The rash is characterized by
pruritus and appears as a thick, hyperkeratotic plaque with a
rough or verrucose surface. This form lingers for an average
of 8 years, often perpetuated by scratching.44
Lichen planus affecting the scalp is called follicular
lichen planus or lichen planopilaris. Patients present with
patchy alopecia and pinpoint, hyperkeratotic follicular pap-
ules that can lead to scarring if left untreated.44
Oral lichen planus most commonly affects the buccal
mucosa, but the tongue and lips can also be affected. Mucous
membrane involvement occurs more in women (2:1) and
slightly later than cutaneous disease, usually in the sixth
decade of life. Examination of the oral cavity will reveal
mucous membranes covered in a lacy, white reticular pattern;
these lesions are usually asymptomatic. The mucous mem-
branes, however, may ulcerate either locally or extensively,
which is called erosive mucosal lichen planus. These are very
painful lesions and may become superinfected with fungus or
bacteria.44
Genital lichen planus appears as violaceous papules on
the vulva or glans penis. In women, the vaginal mucosa can
become friable and erythematous with the potential to form
vaginal or labial adhesions. A variant of mucosal lichen
planus, called vulvovaginal-gingival syndrome, is character-
ized by erosion and desquamation involving the vulva, va-
gina, and gingiva. This variant is particularly resistant to
treatment.44
Lichen planus is a clinical diagnosis based on charac-
teristic appearance and distribution of the rash. Buccal in-
volvement should prompt an evaluation for white Wickham
striae. A patient’s medications should also be reviewed to
rule out drug-induced rash. Skin biopsy can confirm the
diagnosis using direct immunofluorescence, which shows
globular deposits of IgG, IgM, IgA, and complement and
linear basement membrane deposits of fibrin and fibrinogen.44
Most cases of lichen planus spontaneously resolve in 1
to 2 years, though oral lesions tend to be more chronic and
can last for several years. Cutaneous lichen planus can be
treated with moderate- to high-potency topical corticosteroids
twice daily for 2 to 3 weeks. Oral corticosteroids can be used
for more severe, generalized disease, using 30 to 60 mg of
prednisone once daily for 4 to 6 weeks and tapered for an
equal length of time. The oral retinoid acitretin (30 mg/d) is
an effective steroid-sparing agent with proven efficacy.80,81
Oral antihistamines can be used to help soothe pruritus. Other
treatment options for cutaneous disease include intralesional
steroids, phototherapy,82 azathioprine,83 and cyclosporine.84
Genital lesions should be treated with topical corticosteroids
whereas scalp and hypertrophic lesions can be treated with
either topical or intralesional corticosteroids.
Oral lesions are usually best treated with high-potency
topical corticosteroids,85,86 but other preparations such as
fluticasone propionate spray or betamethasone sodium phos-
phate mouth rinse can also be used.87 Systemic corticoste-
roids can be used for refractory or ulcerative oral lichen
planus.88 Other therapeutic options for treating oral lichen
planus include topical calcineurin inhibitors,89 intralesional
corticosteroids,90 dapsone (50 to 150 mg/d),91,92 hydroxy-
chloroquine sulfate (200 to 400 mg/d),93 azathioprine,83,94
topical cyclosporine (100 mg/5 mL),95 methotrexate,96,97 and
mycophenylate mofetil.98,99
PRURIGO SIMPLEX
Prurigo simplex most commonly affects children and
some adults during the spring or summer months. Biting
arthropods of the order Diptera (black flies, house flies, sand
flies, gnats, mosquitos, and midges), Siphonaptera (fleas), and
Acari (ticks) are the most common culprits.
Children are bitten by these insects, become sensi-
tized, and develop a progression of reactions on repeated
bites. Table 3 describes the stage classifications of prurigo
simplex.100
Reactions typically appear within 10 to 15 minutes and
range in size from1 mm to the size of a half-dollar or larger
(Fig. 10). Lesion morphology and symptoms can also vary,
ranging from erythema, whealing, induration, pruritus, vesic-
ulation, hemorrhage, and pain.101 Lesions usually disappear
within 1 hour but can last for weeks. Skin can develop areas
of excoriation or ulceration from habitual scratching, result-
ing in crusts and secondary pyoderma or impetigo. Chronic
lesions, especially when continuously irritated by scratching,
can last for months and eventually leave a scar.
The histopathology of prurigo simplex demonstrates
mild acanthosis, spongiosis, subepidermal edema, erythro-
cyte extravasation, moderate inflammatory cell infiltrate, and
interstitial eosinophilia. A cellular infiltrate comprised of T
cells, macrophages, and eosinophils suggests the pathophys-
iology of papular urticaria is immunologically mediated. It
should be noted, however, that there is no significant evi-
dence in the literature to suggest that these local reactions are
IgE-mediated.
The disease can usually be successfully managed by
avoidance, that is, wearing protective clothing and using
appropriate insect repellents when outdoors. Insect repellents
containing N,N-diethyl-meta-toluamide offer superior, longer
lasting protection compared with non–N,N-diethyl-meta-
toluamide repellents (soy based, botanicals, and wrist
bands).102 Pets should be treated for fleas and ticks because
they are a common reservoir for biting insects. Once lesions
have appeared, low- to moderate-potency topical corticoste-
roids such as triamcinolone 0.025% to 0.1% cream and
systemic antihistamines usually relieve the pruritus. Second-
ary impetigo or pyoderma should be treated with topical or
systemic antibiotics. Parents need to be reassured that the
condition is benign and self-limited, and with time, children
usually “outgrow” these reactions.
TABLE 3. Stage Classifications of Prurigo Simplex
Stage 1 Introduction period with no observable skin reaction
Stage 2 Delayed skin reaction
Stage 3 Immediate skin reaction followed by a delayed reaction
Stage 4 Immediate skin reaction only
Stage 5 No reaction
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TINEA VERSICOLOR
Tinea versicolor is a superficial skin infection caused
by yeasts of the genus Malassazia (also known as Pityrospo-
rum). Malassazia yeast is a normal human cutaneous flora
found especially in areas of the skin with many sebaceous
glands such as the scalp, forehead, shoulders, and trunk. This
organism thrives on lipids and triglycerides; therefore, the
disease is more common in adolescents and young adults who
have oily skin and higher amounts of sebum. It is also a
common problem in tropical regions of the world.44
Lesions can take on a variety of appearances, ranging
from hypopigmented patches, red or salmon-colored macules,
papules, and patches, or tan and dark brown macules or
patches. A fine scale with surrounding erythema is also
commonly present. Lesions usually begin on the upper
trunk and shoulders but can spread to the upper and lower
extremities, head, and neck (Fig. 11). Affected individuals
commonly present with this disease during the warmer
months, indicating that this rash reappears during the same
time each year. The lesions are usually asymptomatic, but
some patients can complain of pruritus, especially if in-
flammation is severe.103
Diagnosis is usually made solely on the basis of the
appearance and distribution of the lesions. If additional test-
ing is necessary, glass slide scrapings of the lesions can be
obtained and stained with potassium hydroxide. Micro-
scopic morphology reveals yeast present as both spores
and hyphae, giving a “spaghetti and meatballs” appear-
ance. Culturing the scrapings is rarely necessary, but when
performed, it should be done on a lipid-containing medium
to ensure proper growth.103
Treatment options include topical agents for limited
disease and oral medications for extensive, refractory, or
recurrent disease. Topical antifungal creams, such as keto-
conazole 2%, miconazole 2%, terbinafine 1%, or clotrimazole
1%, should be applied to affected areas once or twice daily
for 2 to 4 weeks. Shampoos, such as ketoconazole 2% and
selenium sulfide 2.5%, can be applied for several days to treat
both scalp and body lesions. Oral antifungal options include
ketoconazole, 400 mg once weekly for 2 weeks, fluconazole,
300 mg once weekly for 2 weeks, and itraconazole, 200 mg
daily for 7 days.
Once disease remission is achieved, symptomatic relief
is often temporary for tinea versicolor and can recur in 40%
to 60% of cases.44 For such subjects, topical agents can be
used weekly or oral medications monthly for maintenance
therapy.103 Patients should also be informed that skin healing
will continue long after treatment ends and depigmented
areas may require several months to regain natural color.
LICHEN SIMPLEX CHRONICUS
Chronic pruritus, whether from a primary skin disorder
(eczema) or underlying systemic disease (xerosis from hypo-
thyroidism), and repetitive rubbing or scratching eventually
causes the irritated skin to lichenify. Also known as neuro-
dermatitis, lichen simplex chronicus affects areas of the skin
within easy reach, including the following areas in decreasing
order of frequency: lateral leg, scrotum, vulva, anal or pubic
areas, wrists and ankles, upper eyelids, upper back, neck,
external ear canal, extensor forearms near the elbow, poste-
rior auricular area, and the scalp.44 Pruritus may begin from
a nonspecific insult to the skin. Insect bites, minor trauma,
burns, eczema, and contact dermatitis are common instiga-
tors. Pruritus can be intermittent, but scratching or rubbing
provides temporary relief and leads to local erythema. With
continued scratching, the skin then forms thickened plaques
and/or nodules that are hyperpigmented, firm, well demar-
cated, scaly, and erythematous (Fig. 12). If scratching be-
comes too abrasive, linear excoriations or ulcers often de-
velop and increase the risk of superinfection.
The differential diagnosis for lichen simplex chronicus
is extensive, including chronically pruritic conditions such as
FIGURE 11. Tinea versicolor of neck and trunk appears as
confluent, fawn-colored patches. Habif, Clinical Dermatology,
4th ed. Elsevier, 2004.
FIGURE 12. Lichen simplex chronicus (neurodermatitis)
caused by chronic scratching by the opposite heel. Habif,
Clinical Dermatology, 4th ed. Elsevier, 2004.
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atopic dermatitis, lichen planus, contact dermatitis, or sys-
temic diseases such as uremic pruritus or hyperbilirubinemia
secondary to hepatic or cholestatic disease. A history and
physical examination with focused laboratory testing when
necessary will help direct the differential diagnosis. Histo-
logic examination demonstrates hyperkeratosis, acanthosis,
spongiosis, and patches of parakeratosis in the epidermis.
Epidermal thickening occurs in all skin layers with elongation
of rete ridges and pseudoepitheliomatous hyperplasia. Papil-
lary dermal fibrosis with vertical streaking of collagen bun-
dles also occurs.
If chronic pruritus is caused by an underlying disease,
then treatment should target the disease to achieve long-term
relief. In the meantime, the itch-scratch cycle should be
interrupted using topical moisturizers and corticosteroids.
Topical immune modulators, such as tacrolimus or pimecroli-
mus, are also effective antipruritic medications and can be
used on steroid-sensitive areas such as the face or antecubital
skin. Oral antihistamines also are indicated to relieve pruritus
and can help patients who suffer from insomnia from their
pruritus.
CONCLUSIONS
A practicing allergist will commonly encounter patients
with skin diseases. Atopic dermatitis is seen most frequently
because it often relates closely to extrinsic factors such as
environmental or food allergies, but the physician should be
familiar with each of the discussed conditions (Table 4). A
thorough history and physical examination is often all that is
required for an accurate diagnosis. Confirmatory testing op-
tions are limited and treatment with medications using the
most effective dose with the least toxicity should be the goal
to provide relief.
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